Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation

Blood

Volumn 113, Issue 20, 2009, Pages 4894-4902

  Hiruma, Yuko ^a   Honjo, Tadashi ^a   Jelinek, Diane F ^b   Windle, Jolene J ^c   Shin, Jaekyoon ^d   Roodman, G David ^a,e   Kurihara, Noriyoshi ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d Sungkyunkwan University School of Medicine   (South Korea)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN KINASE C DELTA; PROTEIN P62; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; HEAT SHOCK PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SQSTM1 PROTEIN, MOUSE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MICROENVIRONMENT; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN FUNCTION; STROMA CELL; AGED; ANIMAL; BONE MARROW; C57BL MOUSE; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; ENVIRONMENT; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; AGED, 80 AND OVER; ANIMALS; BONE MARROW; CELL PROLIFERATION; CELLS, CULTURED; ENVIRONMENT; FEMALE; HEAT-SHOCK PROTEINS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MIDDLE AGED; MULTIPLE MYELOMA; OSTEOCLASTS; SIGNAL TRANSDUCTION; STROMAL CELLS; UP-REGULATION;

EID: 66549108847     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-08-173948     Document Type: Article

References (37)

1. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584-593.
2. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655-1664.
3. Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood. 2006;108:3992-3996. (Pubitemid 44913267)
4. Michigami T, Shimizu N, Williams PJ, et al. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and α(4)β(1)- integrin enhances production of osteoclast-stimulating activity. Blood. 2000;96:1953-1960.
5. Sanz-Rodriguez F, Teixido J. VLA-4-dependent myeloma cell adhesion. Leuk Lymphoma. 2001;41:239-245.
6. Okada T, Hawley RG, Kodaka M, Okuno H. Significance of VLA-4-VCAM-1 interaction and CD44 for transendothelial invasion in a bone marrow metastatic myeloma model. Clin Exp Metastasis. 1999;17:623-629. (Pubitemid 30337137)
7. Mitsiades CS, McMillin DW, Klippel S, et al. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am. 2007;21:1007-1034, vii-viii. (Pubitemid 350051349)
8. Roodman GD. Bone building with bortezomib. J Clin Invest. 2008;118:462-464.
9. Kim MS, Day CJ, Selinger CI, Magno CL, Stephens SR, Morrison NA. MCP-1-induced human osteoclast-like cells are tartrate-resistant acid phosphatase, NFATc1, and calcitonin receptor-positive but require receptor activator of NFκB ligand for bone resorption. J Biol Chem. 2006;281:1274-1285.
10. Nimmanapalli R, Gerbino E, Dalton WS, Gandhi V, Alsina M. HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma. Br J Haematol. 2008;142:551-561. (Pubitemid 352020201)
11. Schmidmaier R, Baumann P, Simsek M, Dayyani F, Emmerich B, Meinhardt G. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood. 2004;104:1825-1832. (Pubitemid 39202293)
12. Perez LE, Parquet N, Shain K, et al. Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP. J Immunol. 2008;180:1545-1555.
13. Nefedova Y, Sullivan DM, Bolick SC, Dalton WS, Gabrilovich DI. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood. 2008;111:2220-2229.
14. Dexter TM, Allen TD, Lajtha LG. Conditions controlling the proliferation of haemopoietic stem cells in vitro. J Cell Physiol. 1977;91:335-344. (Pubitemid 8112206)
15. Greenstein S, Krett NL, Kurosawa Y, et al. Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp Hematol. 2003;31:271-282. (Pubitemid 36407603)
16. Billadeau D, Liu P, Jelinek D, Shah N, LeBien TW, Van Ness B. Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6. Cancer Res. 1997;57:2268-2275. (Pubitemid 27247048)
17. Shin J. Mice lacking sqstm2/p62 develop obesity and pre-mature aging. Proceedings of the Days of Molecular Medicine at Wellcome Trust Genome Campus, Cambridgeshire, UK. 2004;95A.
18. Kurihara N, Hiruma Y, Zhou H, et al. Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease. J Clin Invest. 2007;117:133-142.
19. Kurihara N, Chenu C, Miller M, Civin C, Roodman GD. Identification of committed mononuclear precursors for osteoclast-like cells formed in long term human marrow cultures. Endocrinology. 1990;126:2733-2741. (Pubitemid 20173068)
20. Kurihara N, Suda T, Miura Y, et al. Generation of osteoclasts from isolated hematopoietic progenitor cells. Blood. 1989;74:1295-1302. (Pubitemid 19227438)
21. Hiruma Y, Kurihara N, Subler MA, et al. A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment. Hum Mol Genet. 2008;17:3708-3719.
22. Zannettino AC, Harrison K, Joyner CJ, Triffitt JT, Simmons PJ. Molecular cloning of the cell surface antigen identified by the osteoprogenitor-specific monoclonal antibody, HOP-26. J Cell Biochem. 2003;89:56-66. (Pubitemid 36459098)
23. Shur I, Marom R, Lokiec F, Socher R, Benayahu D. Identification of cultured progenitor cells from human marrow stroma. J Cell Biochem. 2002;87:51-57. (Pubitemid 34969147)
24. Stewart K, Monk P, Walsh S, Jefferiss CM, Letchford J, Beresford JN. STRO-1, HOP-26 (CD63), CD49a and SB-10 (CD166) as markers of primitive human marrow stromal cells and their more differentiated progeny: a comparative investigation in vitro. Cell Tissue Res. 2003;313:281-290.
25. Oba Y, Lee JW, Ehrlich LA, et al. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp Hematol. 2005;33:272-278. (Pubitemid 40261308)
26. Ishitsuka K, Hideshima T, Neri P, et al. p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br J Haematol. 2008;141:598-606. (Pubitemid 351667613)
27. Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer. 2006;42:1564-1573.
28. Tanaka S, Nakamura I, Inoue J, Oda H, Nakamura K. Signal transduction pathways regulating osteoclast differentiation and function. J Bone Miner Metab. 2003;21:123-133. (Pubitemid 41184293)
29. Diradourian C, Le May C, Cauzac M, Girard J, Burnol AF, Pegorier JP. Involvement of ZIP/p62 in the regulation of PPARalpha transcriptional activity by p38-MAPK. Biochim Biophys Acta. 2008;1781:239-244.
30. Nguyen AN, Stebbins EG, Henson M, et al. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Exp Cell Res. 2006;312:1909-1923. (Pubitemid 43776012)
31. Golay J, Cuppini L, Leoni F, et al. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia. 2007;21:1892-1900. (Pubitemid 47299961)
32. Menaa C, Reddy SV, Kurihara N, et al. Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. J Clin Invest. 2000;105:1833-1838. (Pubitemid 30421765)
33. Sun SG, Lau YS, Itonaga I, Sabokbar A, Athanasou NA. Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation. J Pathol. 2006;209:114-120.
34. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene. 2001;20:4519-4527. (Pubitemid 32772434)
35. Xing L, Bushnell TP, Carlson L, et al. NF-κB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J Bone Miner Res. 2002;17:1200-1210.
36. Rossa C Jr, Liu M, Kirkwood KL. A dominant function of p38 mitogen-activated protein kinase signaling in receptor activator of nuclear factor-κB ligand expression and osteoclastogenesis induction by Aggregatibacter actinomycetemcomitans and Escherichia coli lipopolysaccharide. J Periodontal Res. 2008;43:201-211.
37. Duran A, Serrano M, Leitges M, et al. The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell. 2004;6:303-309. (Pubitemid 38190368)